Feeds:
Posts
Comments

Archive for the ‘LPBI Management’ Category


Data Architecture for Blockchain Deployment of Digital Assets: LPBI IP Asset Classes I,II,III

Author: Aviva Lev-Ari, PhD, RN

 

Distinction between A and B, below

  • A.  1.0 LPBI – 2012–2020 – IP Assets available for sale

  • B.  2.0 LPBI – 2021–2025 – IP Assets under construction – WILL BE AVAILABLE FOR SALE

 

A.  1.0 LPBI – 2012–2020 – IP Assets available for sale

 

A.1 A List of Scientific articles N=6,000 

STORED in Excel file run on 6/30/2020 and 12/31/2020

 

They need to be Indexed by several keys:

A.1.1  Author Name

A.1.2  Article Title

A.1.3  Category of Research, see article example , below

For the Cancer category

  • we have the following tree structure
  • System had data on how many articles are in each category
  •  Cancer – General
  •  Cancer and Current Therapeutics
    •  interventional oncology
      •  Breast Cancer – impalpable breast lesions
      •  Prostate Cancer: Monitoring vs Treatment
  •  CANCER BIOLOGY & Innovations in Cancer Therapy
    •  Anaerobic Glycolysis
    •  Cachexia
    •  Cancer Genomics
      •  Circulating Tumor Cells (CTC)
        •  Liquid Biopsy Chip detects an array of metastatic cancer cell markers in blood
          •  mRNA
        •  MagSifter chip
      •  KRAS Mutation
      •  Li-fraumeni syndrome.
      •  TP53 – Germline mutations
    •  cancer metabolism
    •  Funding Opportunities for Cancer Research
    •  Genomic Expression
    •  Glioblastoma
    •  Hexokinase
    •  Loss of function gene
    •  Metabolic Immuno-Oncology
    •  Metastasis Process
    •  Methylation
    •  Microbiome and Responses to Cancer Therapy
    •  Monoclonal Immunotherapy
    •  mtDNA
    •  Oxidative phosphorylation
    •  Pancreatic cancer
    •  Pyruvate Kinase
    •  The NCI Formulary
    •  tumor microenvironment
    •  Warburg effect
  •  Cancer Informatics
  •  Cancer Prevention: Research & Programs
  •  Cancer Screening
  •  Cancer Vaccines: Targeting Cancer Genes for Immunotherapy
    •  Engineering Enhanced Cancer Vaccines

A.1.4  Type of article: by the role of the author: 

  • If the Author is Curator THAN this article is a curation
  • If the Author is Reporter THEN this article is a Scientific reporting article

A.1.5  Article Abstract will be a WordCloud created by ML – one image per article

Example

Is the Warburg Effect the Cause or the Effect of Cancer: A 21st Century View?  <<<<<<<<< Article Title

Author: Larry H. Bernstein, MD, FCAP  <<<<<<<<< Author’s Name

https://pharmaceuticalintelligence.com/2012/10/17/is-the-warburg-effect-the-cause-or-the-effect-of-cancer-a-21st-century-view/   <<<<<<< URL

  • The system provides: “Related” what you named associated, see below  will need to be placed in the article description
  • The system provides: “Posted in” – meaning  ALL the categories of research checked off by the author that this article belong to by the SUBJECT MATTER of the article

EXAMPLE for Related” what you named associated

Related

What can we expect of tumor therapeutic response?

In “Biological Networks, Gene Regulation and Evolution”

WordCloud Visualization of LPBI’s Top Twelve Articles by Views at All Time and their Research Categories in the Ontology of PharmaceuticalIntelligence.com

In “Academic Publishing”

AMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth In Vivo

In “Biological Networks, Gene Regulation and Evolution”

Examples for >>>>>>>> Category of Research  live links listing in parenthesis number of articles in one category

Posted in Biological NetworksCANCER BIOLOGY & Innovations in Cancer TherapyCell BiologyDisease BiologyGenome BiologyImaging-based Cancer Patient ManagementInternational Global Work in PharmaceuticalLiver & Digestive Diseases ResearchMetabolomicsMolecular Genetics & PharmaceuticalNutritionPharmaceutical Industry Competitive IntelligencePharmaceutical R&D InvestmentPopulation Health ManagementProteomicsStem Cells for Regenerative MedicineTechnology Transfer: Biotech and Pharmaceutical | Tagged Adenosine triphosphateATPGlycolysisHypoxia-inducible factorsKrebLactate dehydrogenaseMammalian target of rapamycinMitochondrionWarburg Effect | 40 Comments

Below, an excerpt from the 6,000 LIST: Top Posts by VIEWS for all days ending 2020-06-02 (Summarized)

 

All Time      
Title Views Author Name Type of Article
Home page / Archives 676,690 Internet Access Tabulation
Is the Warburg Effect the Cause or the Effect of Cancer: A 21st Century View? 17,117 Larry H. Bernstein, MD, FACP Investigator Initiated Research
Recent comprehensive review on the role of ultrasound in breast cancer management 14,242 Dr. D. Nir Commission by Aviva Lev-Ari, PhD, RN
Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran) 13,839 Dr. Pearlman, MD, PhD, FACC & Aviva Lev-Ari, PhD, RN Commission by Aviva Lev-Ari, PhD, RN
Paclitaxel vs Abraxane (albumin-bound paclitaxel) 13,709 Tilda Barliya, PhD Investigator Initiated Research
Apixaban (Eliquis): Mechanism of Action, Drug Comparison and Additional Indications 8,230 Aviva Lev-Ari, PhD, RN Investigator Initiated Research
Clinical Indications for Use of Inhaled Nitric Oxide (iNO) in the Adult Patient Market: Clinical Outcomes after Use, Therapy Demand and Cost of Care 7,903 Dr. Pearlman, MD, PhD, FACC & Aviva Lev-Ari, PhD, RN Investigator Initiated Research
Mesothelin: An early detection biomarker for cancer (By Jack Andraka) 6,540 Tilda Barliya, PhD Investigator Initiated Research
Our TEAM 6,505 Internet Access Tabulation
Biochemistry of the Coagulation Cascade and Platelet Aggregation: Nitric Oxide: Platelets, Circulatory Disorders, and Coagulation Effects 5,221 Larry H. Bernstein, MD, FACP Investigator Initiated Research
Interaction of enzymes and hormones 4,901 Larry H. Bernstein, MD, FACP Commission by Aviva Lev-Ari, PhD, RN
Akt inhibition for cancer treatment, where do we stand today? 4,852 Ziv Raviv, PhD Investigator Initiated Research
AstraZeneca’s WEE1 protein inhibitor AZD1775 Shows Success Against Tumors with a SETD2 mutation 4,535 Stephen J. Williams, PhD Investigator Initiated Research
The History and Creators of Total Parenteral Nutrition 4,511 Larry H. Bernstein, MD, FACP Commission by Aviva Lev-Ari, PhD, RN
Newer Treatments for Depression: Monoamine, Neurotrophic Factor & Pharmacokinetic Hypotheses 4,365 Zohi Sternberg, PhD Investigator Initiated Research
FDA Guidelines For Developmental and Reproductive Toxicology (DART) Studies for Small Molecules 4,188 Stephen J. Williams, PhD Investigator Initiated Research
The Centrality of Ca(2+) Signaling and Cytoskeleton Involving Calmodulin Kinases and Ryanodine Receptors in Cardiac Failure, Arterial Smooth Muscle, Post-ischemic Arrhythmia, Similarities and Differences, and Pharmaceutical Targets 4,038 Dr. Pearlman, MD, PhD, FACC, Larry H. Bernstein, MD, FACP & Aviva Lev-Ari, PhD, RN Commission by Aviva Lev-Ari, PhD, RN
Founder 3,895 Aviva Lev-Ari, PhD, RN Investigator Initiated Research

EndFragment

A.2 A List of 16 e-BOOKS

https://lnkd.in/ekWGNqA

 

A.2.1   Each book is made of articles included in the N=6,000

A.2.2 Books will list the URL of each book

http://www.amazon.com/dp/B00DINFFYC

http://www.amazon.com/dp/B018Q5MCN8

http://www.amazon.com/dp/B018PNHJ84

http://www.amazon.com/dp/B018DHBUO6

http://www.amazon.com/dp/B013RVYR2K

http://www.amazon.com/dp/B012BB0ZF0

http://www.amazon.com/dp/B019UM909A

http://www.amazon.com/dp/B019VH97LU

http://www.amazon.com/dp/B071VQ6YYK

https://www.amazon.com/dp/B075CXHY1B

https://www.amazon.com/dp/B076HGB6MZ

https://www.amazon.com/dp/B078313281

https://www.amazon.com/dp/B078QVDV2W

https://www.amazon.com/dp/B07MGSFDWR

https://www.amazon.com/dp/B07MKHDBHF

https://www.amazon.com/dp/B08385KF87

A.3 A List of e-Proceedings and Tweet Collections

A.3.1 each entry is an article included in N=6,000

B.   2.0 LPBI – 2021–2025 –

IP Assets under construction –

WILL BE AVAILABLE FOR SALE

 

B.1 Journal articles

  • Will be subjected to ML and a NEW product will be created
  • Instead of N=6,000 article – we will have N= 6,000 Medical INSIGHTS

B.2 16 e-Books

  • Will be subjected to ML and a NEW product will be created
  • Instead of 16 Books – we will have 16 COLLECTIONS of Medical INSIGHTS derived from Text Analysis of ONLY the articles included on each Volume
  • 16 e-Books will become 16 AUDIO BOOKS
  • 16 e-Books will become 16 Books in Japanese, Spanish and Russians

 

B.3 eProceedings & Tweet collections

  • Will be subjected to ML and a NEW product will be created
  • Instead of 60 e-Proceedings and 30 Tweet collections we will get 100 Business INSIGHTS Collections in the domain of each conference

 

We believe that Blockchain will enable STORAGE of each item that will be available for sale

  • LPBI will have team members Bundling items per customer needs 
  • Promotion can be done OUTSIDE the Blockchain system – STIRRING Customers to the Blockchain transaction system for TRADE and recording of transactions
  • That is true for A and for B, below

A.   1.0 LPBI – 2012–2020 – IP Assets available for sale

B.   2.0 LPBI – 2021–2025 – IP Assets under construction – WILL BE AVAILABLE FOR SALE

 

Data Architecture Questions

 

  1. In what data format is the content stored? In other words, is the content in image pdfs, searchable document pdfs, html, xls, word documents, text files, or some other form?

Example: TEXT

Versions of LPBI Group’s Elevator Pitch: 2.0 LPBI Group’s Team – In Our Own Words

My proposed Elevator Pitch

For the first time in the ten years of our private ownership, the opportunity to acquire the Inventor of Scientific curation has become a reality, Available for Transfer of ownership.

You can own a portfolio of Intellectual Property Assets that commands ~2MM e-Readers and offers ~6,000 of the best interpretive articles in five specialties of Medicine and Life Sciences. Pages of our 16 books have been downloaded ~125,000 times and over 100 of the top biotech and medical conferences were covered in real time and recorded in writing and Tweets. New strategies in AI and Blockchain are now applied on LPBI’s content for INSIGHT searches and pattern recognition by automated Machine Learning algorithms for use in drug discovery and drug repurposing. All of LPBI’s content was created by our Experts, Authors, Writers (EAWs).

    • We UPLOAD MS Word file NOT PDF
    • INVENTORY is stored in Excel
    • Top Posts for all days ending 2020-11-16 (Summarized)
      1. 7 Days |30 Days |Quarter |Year |All time
    • All Time
  • Title
  • Views
  • 716,030
  • 17,263
  • 15,300
  • 14,341
  • 14,006
  • 8,770
  • 8,398
  • 6,632
  • 6,580
  • 5,536
  • 5,304
  • 5,056
  • 4,899
  • 4,712
  • 4,665
  • 4,453
  • 4,416
  • 4,335
  • 4,206
  • 4,126
  • 4,118
 
  1. Within each content file or dataset, is the content metadata already defined, or would we need to parse the file to pull out the metadata? In other words, in the file for a journal article, do you already have the author, date, abstract, keywords, etc. defined as discrete pieces of data, or is all of this information embedded within the overall file?

YES

They need to be Indexed by several keys:

A.1.1  Author Name

A.1.2  Article Title

A.1.3  Category of Research

 

  1. Do you expect to use a single type of subscription (such as a monthly subscription), or will different types of data have different types 

of subscription options (similar to how journals offer both one-time 24-hour subscriptions to a single article as well as monthly ongoing subscriptions)?

We wish to SELL ARTICLE DOWNLOAD vs Subscriptions

  1. Does the marketplace need to include fuzzy search (i.e., the ability to find content based on “similar to” criteria, instead of just exact match searches)? Does it need to present the user with related content, or only the content that was searched for?

Our system attaches to each article RELATED content

  1. We assume that the marketplace is not intended to replace your current LPBI company website? We are not scoping the quote to include a full website rebuild; it is assumed that the marketplace is separate (and your users would access the marketplace via the LPBI website).

YES – the digital store will connect to our newly to be designed web site for 2.0 LPBI on WordPress.com

  • The digital store is the FORUM to buy goods by digital download of content
  • $30 for One digital article or Audio article
  • REFERRAL to Amazon Website to buy a book or the book in AUDIO format or a book in Japanese and Spanish – Russia is not served by Amazon – we can sell directly to consumers
  • $100 download of an e-Proceedings for a Conference or the Tweet collection

For 2.0 LPBI Products

Bundles of Insights for Targeted Industries – B–to-B

  • Tier #1:  Insights for drug discovery embedded in consulting engagements
  • Tier #2:  Insights for drug repurposing embedded in consulting engagements
  • Tier #3:  Insights for Health Care Insurers embedded in consulting engagements

Bundles of insights for theScientific Community – B–to-C

Read Full Post »


Versions of LPBI Group’s Elevator Pitch: 2.0 LPBI Group’s Team – In Our Own Words

My proposed Elevator Pitch

For the first time in the ten years of our private ownership, the opportunity to acquire the Inventor of Scientific curation has become a reality, Available for Transfer of ownership.

You can own a portfolio of Intellectual Property Assets that commands ~2MM e-Readers and offers ~6,000 of the best interpretive articles in five specialties of Medicine and Life Sciences. Pages of our 16 books have been downloaded ~125,000 times and over 100 of the top biotech and medical conferences were covered in real time and recorded in writing and Tweets. New strategies in AI and Blockchain are now applied on LPBI’s content for INSIGHT searches and pattern recognition by automated Machine Learning algorithms for use in drug discovery and drug repurposing. All of LPBI’s content was created by our Experts, Authors, Writers (EAWs).

  • Bold vision for the coming five years includes: All content will be converted by Machine Learning algorithms to search for all hyper-graphs and their expression in WordClouds.
  • From text we will convert content to Audio. From English Text we will translate to foreign languages like Japanese, Spanish and Russian.
  • From Open Access we will transition to Blockchain transaction networks.
  • From Digital Cloud-based biographies we will create audio and video Podcasts
  • From a sole owner-operator status we will transition to Joint-Ventures to M&A and Partnerships

Our Transformational transition is two dimensional:

  1. Our deep expertise and innovations in media platforms and content creation will have new directions: we will focus on other Countries (x,y,z) and Geographical regions: i.e., EU and South-East Asia
  2. Our created content will become the basis of our content mining and the subject of managed computerized text analysis under supervised learning guided by our own team of experts.

We are fundamentally a media system integrator, platform developer and platform customizer; an innovative and creative scientific content creator. We function as a fully vertically integrated BioMed creator and generator of knowledge for health information markets via our own Journal articles, BioMed e-Series of Books, Conference e-Proceedings, Podcasts, and additional five strategies https://pharmaceuticalintelligence.com/vision/

 

My proposed Elevator Pitch

1. Strong scientific curation  makes basic research readily available to wide range of scholars, practitioners and students in biomedical science

2. The books are convenient and comprehensive compendia of the latest scholarship.

3. The updating methodology keeps material current

4. Reporting on conferences and meetings gives the audience early access to the latest technologies in biomedicine

5. Curation methodology is transferable across disciplines and languages allowing for big international and interdisciplinary markets

6. The pricing analysis has been carefully researched across multimedia platforms

 

My proposed Elevator Pitch

The complex and rapid deluge of scientific information, absence of a collaborative, open environment to produce transformative innovation, and dearth of alternative ways to disseminate scientific findings has led to major operational inefficiencies in the biomedical and pharma industries, to the tune of millions of dollars per year. These issues have driven the need for a more context-driven architecture for knowledge and discourse within the biomedical arena.  The process of curation decreases time for assessment of current trends adding multiple insights, analyses WITH an underlying METHODOLOGY, provides insights from WHOLE scientific community on multiple WEB 2.0 platforms, and makes use of new computational and Web-based tools to provide interoperability of data, reporting of findings.

Our Ideas are Products of our Environment

At Leaders in Pharmaceutical Business Intelligence (LPBI) Group website owner and Editor-in-Chief,  Aviva Lev-Ari, PhD, RN has been developing a strategy for the

facilitation of Global access to Biomedical knowledge rather than the access to sheer search results on Scientific subject matters in the Life Sciences and Medicine”. According to Aviva, “for the methodology to attain this complex goal it is to be dealing with popularization of ORIGINAL Scientific Research via Content Curation of Scientific Research Results by Experts, Authors, Writers using the critical thinking process of expert interpretation of the original research results.

LPBI’s copyrighted curation process includes synthesis, analysis, and interpretation of complex medical and scientific areas by our highly trained and well-regarded staff.  It creates vast, universally accessible scientific content, over multiple platforms within the Life Sciences, Medical, and Allied Health Care professional fields. This curative process establishes new connections and produces new and transformative ideas.

Using our curation methodology, LPBI has produced an open-access online scientific journal, a series of 16 BioMed e-books, and Real-time press coverage of scientific conferences, all of which are optimally designed for novel Text Analysis methods using leading AI, ML and NLP algorithms from 3rd parties software applied on LPBI’s own content customizing the applications for the needs developed by LPBI in the classification and clustering of the Semantics in our contents: Journal articles (6,000) e-Books (16) Conferences content (100).

Through use of AI, ML, NLP, Audio Podcasts and additional modern technology, we are postulating revenues on the order of $50MM to the acquirer by exploiting our content.

 

My proposed Elevator Pitch

Currently, there is a digital information explosion in both the Life Sciences and Medical arenas. Tracking new information and discoveries, while guarding against obsolescence, is a major challenge for scientists working in these fields.

To overcome these challenges, the Leaders in Pharmaceutical Business Intelligence (LPBI) Group was created in 2012 by Dr. Aviva Lev-Ari.

LPBI (previously an equity sharing, non-profit entity) is now making its intellectual and digital intellectual properties available for sale to outside entities that are willing to take over and extend our reach.

Through use of AI, NLP, Audio Podcasts and additional advanced Machine Learning technologies, we are postulating revenues on the order of $50MM to the acquirer by exploiting our content

LPBI’s copyrighted curation process includes synthesis, analysis, and interpretation of complex medical and scientific areas by our highly trained and well-regarded staff. It creates vast, universally accessible scientific content, over multiple platforms within the Life Sciences, Medical, and Allied Health Care professional fields.

This enables the LPBI Group to respond to the needs of our scientific audiences, guarding against information obsolescence and overload, through innovative digital technologies and solutions, via:

  • An open-access online scientific journal
  • A series of 16 BioMed e-books.
  • Real-time press coverage with real-time Twitter posting of speakers quotes during conferences.

These have been made widely available to the scientific and non-research community by the Open Access feature of LPBI’s Journal’s website PharmaceuticalIntelligence.com.

 

My proposed Elevator Pitch

The Leaders in Pharmaceutical Business Intelligence (LPBI) Group was created in 2012 by Dr. Aviva Lev-Ari.

The effort filled a major need for information technology by the development, refinement and fulfillment of CURATION, which combines literature review, experience, and expertise into a guided-tour of accomplishments and pathways for understanding current issues in biology, chemistry, medicine and therapeutics, identifying opportunities and seizing leadership in the development and utilization of therapeutic opportunities. Through practice, recruitment, and refinement of methods, a large body of information and information management technology was amassed, along with a large following. This body of informatics and methodology is now available for commercial use to own, nurture and grow a valuable audience.

The available material includes:

  • An open-access online scientific journal
  • A series of 16 BioMed e-books.
  • Unique coverage of speakers quotes during conferences.
  • Curated cumulative knowledge organized as a path to leadership

The reach includes video and audio podcasts as well as a unique annotated chain of web links that expedites comprehensive mastery of biologic, medical, and pharmaceutical curriculum. The curation overcomes limitations of publication bias to bring the viewers to the leading edge of capabilities pointing to opportunities ripe for the exciting future.

 

My proposed Elevator Pitch

 

My proposed Elevator Pitch

Our world is full of device screens, we keep them in our hands (hand-held devices) and surround ourselves with them using IOT. What if there was a way this new network brought world’s best resources and knowledge, as a normal part of life ?

To overcome the digital information explosion in both life sciences and medical field, the Leaders in Pharmaceutical Business Intelligence (LPBI) Group was created in 2012 by Dr. Aviva Lev-Ari.

LPBI (previously an equity sharing, non-profit entity) is now making its intellectual and digital intellectual properties available for sale to outside entities that are willing to take over and extend our reach. Tracking new information and discoveries, while creating new paths for current issues in biology, chemistry, medicine and therapeutics.

Aided by artificial intelligence and neurolinguistic programming LPBI has created its own curation process which includes synthesis, analysis, and interpretation of complex medical and scientific areas as well as various audio podcasts of Key Opinion Leaders.

The symbiotic nature of LPBI group allows us to respond to the needs of our scientific audiences, guarding against information obsolescence and overload, through innovative digital technologies and solutions, via:

  • An open-access online scientific journal
  • A series of 16 BioMed e-books.
  • Real-time press coverage with real-time Twitter posting of speakers quotes during conferences.

Our resources have been widely accessible to the scientific and non-research community by the Open Access feature of LPBI’s Journal’s website  PharmaceuticalIntelligence.com.

 

My proposed Elevator Pitch

About LPBI Group
Leaders in Pharmaceutical Business Intelligence Group (“LPBI Group”) is a leading, global pharmaceutical news source that provides scientific and medical curated and general-reporting content to a wide range of thought leader audiences.
There are three interrelated areas — an open-access online scientific journal, including a selection of timely podcasts and newsletters, a series of 16 BioMed e-books and real-time press coverage of medical and scientific conferences. The Group also synthesizes, analyzes and interprets therapeutic and disease information in various disciplines within biomedicine and life sciences through electronic publishing in the cloud with the goal of advancing knowledge and research efforts of the scientific and business community. Additionally, the Group applies existing software algorithms, i.e., NLP, ML, AI on its own content as they develop expert-driven interpretation of the medical text analysis outcomes.
The Group, comprised of a highly experienced team in science, medicine and business, was created in 2012 by Dr. Aviva Lev-Ari, Ph.D., R.N. This team reports on currently available medical and scientific information on a variety of subjects in the domains of BioMed, Biotech, MedTech, BioScience, Medicine, Pharmaceuticals, Life Sciences and Health care. These subjects are classified under 700+ research categories forming the ontology of the Journal of PharmaceuticalIntelligence.com.
Today, there is a considerable amount of digital information in the fields of medicine and life sciences. The Group is actively responding to the scientific and business community with technologies and solutions that help advance the world of research by using the methodology of curations of scientific findings from the perspective of clinical interpretation of the experimental results to communicate science.

My proposed Elevator Pitch

  • We are in the higher digital-healthcare / electronic-healthcare arena a growing market of multiple unicorns, and a field that is in the rise. Our niche is trendy, high valued field, current trends are well known also to us. We understand the market as well as the scientific arena
  • We bring to the market the second opinion concept that is working in heath care for so many years to the scientific research for pharmaceutical R&D, medical and life science education.
  • We also offer a synthetic approach for the presented science and current knowledge as known and understood by the expert in his subject matter.
  • LPBI’s future will be in AI, ML, NLP – contextual Medical Text Analysis, digital-medicine and digital education
  • We solve the problem of attention in a tsunami of publication and research done and help increase productivity of R&D workers, analysts, academic researchers, IP workers, regulators, and healthcare providers.
  • We are showing traction and well known multiple monetization strategies https://pharmaceuticalintelligence.com/vision/
  • We can base our projections on a solid well know business model in the industry: “Pay for scientific content.”

 

George N. Gamota, Jr. – External Business Relations

The company is a multimedia publishing company, specializing in making available unique, curated, peer reviewed life science, medical and pharmaceutical research information of interest to whom?.  Its unique repository of data includes: X, Y, and Z, via print, e-articles, e-books, podcasts, etc.

Read Full Post »


Reporter: Daniel Menzin

LPBI Twitter Handles & Twitter IDs:

Pharma_BI, 549331093
AVIVA1950, 271204092

Instructions:

  1. Run the Python code. This will take a long time.
    Once it is finished executing it will give you four separate CSV files with data for @AVIVA1950.
  2. Find the CSV files in the project folder for whatever IDE you’re using.
  3. Load the files into Excel, and then paste the CSV data into the templated Excel file provided for @AVIVA1950.
  4. Once you’ve transferred all the data from the four CSV files to the Excel template, you can now repeat the same process for the @Pharma_BI template.
    To do this you’ll need to change the Id_txt variable in the code.
    Here is the information to plug in: Pharma_BI, 549331093
  5. Run the code again for @Pharma_BI and repeat this process.
  6. Generate the plots you need for each spreadsheet.

Note: N/A indicates that there was an encoding error, likely due to foreign letters or other symbols being present in the Twitter data.
This does not necessarily mean that the data in this row is not valuable.

Read Full Post »